KCM
MACK

Knoll Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Knoll Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-20,410
Closed -$809K – 17
2014
Q1 		$809K Buy
20,410
+10,877
+114% +$465K 0.42% 9
2013
Q4 		$400K Buy
+9,533
New +$276K 0.2% 12

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Knoll Capital Management's MACK Position: Q2 2014 in Review

Knoll Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2014, closing a stake of 20,410 shares — an estimated $809K sold.

Knoll Capital Management first reported a position in MACK in Q4 2013 and held it in 2 quarters. The position peaked at $809K in Q1 2014. 121 funds tracked by Wall St. Rank hold MACK as of Q2 2014.

  • Knoll Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Knoll Capital Management sold 20,410 Merrimack Pharmaceuticals, Inc. shares in Q2 2014, an estimated $809K.
  • Knoll Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 2 quarters.
  • Knoll Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $809K in Q1 2014.
  • 121 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2014.

Based on Knoll Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.